Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2], Sheng Shi, M.D. [3]
Empiric Therapy
Community-Acquired Meningitis
▸ Newborn, Age <1 Week
▸ Newborn, Age 1—4 Weeks
▸ Infant & Children
▸ Adult, Age <50 Years
▸ Adult, Age >50 Years
▸ Immunocompromised
▸ Recurrent
Infant & Children
|
Preferred Regimen
|
▸ Vancomycin 15 mg/kg IV q6h to achieve serum trough concentrations of 15–20 μg/mL
|
PLUS
|
▸ Cefotaxime 225—300 mg/kg/day IV q6–8h OR ▸Ceftriaxone 80—100 mg/kg/day IV q12–24h
|
|
Adult, Age <50 Years
|
Preferred Regimen
|
▸ Vancomycin 30–60 mg/kg/day IV q8–12h to achieve serum trough concentrations of 15–20 μg/mL
|
PLUS
|
▸ Cefotaxime 8–12 g/day IV q4–6h OR ▸Ceftriaxone 2 g IV q12h
|
† Add Ampicillin 2 g IV q4h (50 mg/kg IV q6h for children) if meningitis caused by Listeria monocytogenes is also suspected.
|
|
Healthcare-Associated Meningitis
Adapted from Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693-702.[1]
References
Template:WikiDoc Sources